Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Total Non-Current Liabilities (2016 - 2025)

Haemonetics (HAE) has 15 years of Total Non-Current Liabilities data on record, last reported at $1.5 billion in Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 1.21% year-over-year to $1.5 billion; the TTM value through Dec 2025 reached $1.5 billion, down 1.21%, while the annual FY2025 figure was $1.6 billion, 34.58% up from the prior year.
  • Total Non-Current Liabilities reached $1.5 billion in Q4 2025 per HAE's latest filing, down from $1.5 billion in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $1.6 billion in Q1 2025 and bottomed at $976.2 million in Q3 2022.
  • Average Total Non-Current Liabilities over 5 years is $1.2 billion, with a median of $1.1 billion recorded in 2022.
  • The widest YoY moves for Total Non-Current Liabilities: up 104.19% in 2022, down 4.29% in 2022.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $1.0 billion in 2021, then increased by 1.26% to $1.0 billion in 2022, then increased by 15.33% to $1.2 billion in 2023, then rose by 29.94% to $1.5 billion in 2024, then decreased by 1.21% to $1.5 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $1.5 billion in Q4 2025, $1.5 billion in Q3 2025, and $1.5 billion in Q2 2025.